KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Shares Outstanding (Weighted Average) (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $56.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 2.45% to $56.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.5 million through Dec 2025, up 2.45% year-over-year, with the annual reading at $56.5 million for FY2025, 2.45% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $56.5 million at Supernus Pharmaceuticals, roughly flat from $56.6 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $56.6 million in Q3 2025, with the low at $52.9 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $54.4 million, with a median of $54.5 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) rose 0.62% in 2022, then grew 2.54% in 2025.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $53.1 million in 2021, then rose by 1.07% to $53.7 million in 2022, then grew by 1.62% to $54.5 million in 2023, then grew by 1.03% to $55.1 million in 2024, then increased by 2.45% to $56.5 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $56.5 million, $56.6 million, and $56.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.